Clinical Review

Type 1 vs Type 2 Diabetes: Differences, Diagnosis, Treatment (NCLEX Review)

Quick answer: Type 1 diabetes is an autoimmune disease that destroys the insulin-making beta cells of the pancreas, so the body makes little or no insulin and needs insulin for life. Type 2 diabetes is insulin resistance combined with a gradual loss of insulin secretion; it makes up 90-95% of cases and is treated with lifestyle change, oral or injectable medicines and, when needed, insulin. Type 1 is prone to DKA; type 2 is more prone to HHS. Both types are diagnosed with the same ADA criteria, such as an A1C at or above 6.5%.

On the NCLEX, the type of diabetes predicts the emergency, the medicines and the teaching. Type 1 points you toward DKA, insulin that is never skipped and ketone checks on sick days. Type 2 points you toward HHS, a long list of oral and weekly injectable drugs and the adverse effects that come with each class. Ten practice questions with rationales follow the review.

What is the difference between type 1 and type 2 diabetes?

Type 1 is a problem of insulin production. Type 2 starts as a problem of insulin action and becomes a problem of production over time. The ADA Standards of Care in Diabetes—2026 define type 1 as autoimmune beta-cell destruction that usually leads to absolute insulin deficiency, and type 2 as a nonautoimmune, progressive loss of insulin secretion, frequently on a background of insulin resistance.

Feature Type 1 diabetes Type 2 diabetes
Cause Autoimmune destruction of pancreatic beta cells Insulin resistance plus a gradual, nonautoimmune loss of insulin secretion
Insulin made by the pancreas Little or none (absolute deficiency) Some, but not enough (relative deficiency), falling over the years
Share of all diabetes About 5-10% About 90-95%
Typical age at onset Often childhood or young adulthood, but any age Usually adulthood, but also occurs in children and teens
Body habitus Often lean, with recent unintentional weight loss Most have overweight or obesity, often abdominal
Onset of symptoms Often abrupt: polyuria, polydipsia and weight loss Gradual; often no symptoms for years and found on screening
Lab clues Islet autoantibodies (GAD65, IA-2, ZnT8, insulin); low or undetectable C-peptide Autoantibodies negative; C-peptide present, though insulin output declines over time
Ketosis and DKA risk High; about half of children are in DKA at diagnosis Low; DKA usually needs a trigger such as severe illness, glucocorticoids or an SGLT2 inhibitor
Typical hyperglycemic crisis DKA HHS, especially in older adults
Insulin requirement Required from diagnosis to survive Often not needed at first; many need it later
Typical treatment Basal and mealtime insulin by injection or pump, carbohydrate counting, continuous glucose monitoring Lifestyle change plus metformin, a GLP-1 receptor agonist, a dual GIP/GLP-1 receptor agonist, an SGLT2 inhibitor or other agents; insulin when needed
Prevention Cannot be prevented; teplizumab can delay clinical (stage 3) disease in people with stage 2 Risk drops with modest weight loss and regular physical activity

Age and weight are clues, not rules. ADA stresses that both types occur at every age. Type 1 can begin in adulthood and progress slowly (often called latent autoimmune diabetes in adults, or LADA), and type 2 also occurs in children and teens. Features that point toward type 1 include diagnosis before age 35, a BMI under 25 kg/m2, unintentional weight loss, ketoacidosis and a glucose above 360 mg/dL at presentation. Some adults with type 2 diabetes, particularly Black and Hispanic/Latino adults, present in DKA; this is called ketosis-prone diabetes.

NCLEX tip: A lean 12-year-old with weight loss, constant thirst and fruity breath is the classic type 1 stem, and DKA is the danger. An older adult with obesity, fatigue, blurred vision or a slow-healing foot wound is the classic type 2 stem. Items rarely stop at the label; they ask what the label changes about your next action.

Why does type 1 cause ketones when type 2 usually does not?

Without enough insulin, cells cannot take in glucose; the body burns fat instead, and the liver turns the released fatty acids into ketoacids. In type 1 diabetes there is almost no insulin to stop that process, so DKA can develop over hours to a few days. Most people with type 2 diabetes still make enough insulin to hold back ketone production, so the glucose climbs over days to weeks while the client becomes severely dehydrated. That pattern is HHS.

How is diabetes diagnosed? (ADA 2026 criteria)

The ADA uses the same diagnostic criteria for type 1 and type 2 diabetes in people who are not pregnant. Any one of these meets the threshold. These are ADA diagnostic cutoffs; laboratory reference ranges for glucose vary by facility.

Test Diabetes Prediabetes What to know
A1C 6.5% or higher 5.7-6.4% Reflects average glucose over about 2-3 months; no fasting needed
Fasting plasma glucose 126 mg/dL or higher 100-125 mg/dL Fasting means no caloric intake for at least 8 hours
2-hour glucose on a 75-g OGTT (oral glucose tolerance test) 200 mg/dL or higher 140-199 mg/dL Measured 2 hours after a 75-g glucose drink
Random plasma glucose (any time of day) 200 mg/dL or higher with classic symptoms or a hyperglycemic crisis Not used Classic symptoms are polyuria, polydipsia and unexplained weight loss

Unless hyperglycemia is unequivocal (the random-glucose row in the table), the diagnosis needs two abnormal results. They can come from two different tests on the same sample (for example, A1C and fasting glucose) or from the same test repeated at a second visit.

A1C can mislead when red blood cell turnover changes, as in anemia, blood loss, transfusion, hemolysis or pregnancy, and with some hemoglobin variants; ADA says to use plasma glucose criteria in those situations. Once diabetes is confirmed, the next question is which type. ADA recommends standardized islet autoantibody testing in adults whose features overlap with type 1, such as the type 1 clues listed earlier. C-peptide shows how much insulin the pancreas is still making.

Who should be screened?

  • All adults: start testing at age 35, and repeat at least every 3 years if results are normal.
  • Adults of any age with overweight or obesity (BMI 25 kg/m2 or higher, or 23 or higher in people of Asian ancestry) plus at least one risk factor, such as a first-degree relative with diabetes, hypertension or cardiovascular disease.
  • Prediabetes: test every year.
  • History of gestational diabetes: test at least every 1-3 years for life.
  • Children and teens with overweight or obesity and one or more risk factors: consider screening after puberty starts or after age 10, whichever comes first.
NCLEX tip: Do not confuse the diagnostic cutoff with the treatment goal. An A1C at or above 6.5% diagnoses diabetes. An A1C below 7% is an appropriate goal for many nonpregnant adults, with a premeal glucose of 80-130 mg/dL; clients using a continuous glucose monitor aim for more than 70% of readings between 70 and 180 mg/dL.

DKA vs HHS: which crisis goes with which type?

Both crises come from too little effective insulin, and both cause polyuria, polydipsia, dehydration and altered mental status. The dividing line is ketones. The table uses the diagnostic criteria in the ADA 2026 Standards of Care; the full treatment sequence is on the DKA vs HHS comparison page.

Feature DKA HHS
Usual diabetes type More common in young people with type 1; can occur in type 2 Mostly older adults with type 2
Speed of onset Hours to a few days Days to weeks
Glucose At or above 200 mg/dL, or known diabetes at any glucose (many exam items still use above 250 mg/dL) 600 mg/dL or higher
Acid-base Bicarbonate under 18 mEq/L and/or pH below 7.3 pH 7.3 or higher and bicarbonate 15 mEq/L or higher
Ketones Beta-hydroxybutyrate 3.0 mmol/L or higher, or urine ketones 2+ or more Below those levels
Osmolality Often raised, but not the defining feature Total osmolality above 320 mOsm/kg (or effective osmolality above 300)
Key signs Kussmaul respirations, fruity breath, nausea, vomiting, abdominal pain Severe dehydration and altered mental status, from confusion to coma
Mortality with treatment Below 1% Five to ten times higher than DKA

DKA can also occur with a near-normal glucose. About 10% of DKA cases are euglycemic DKA (glucose below 200 mg/dL), and SGLT2 inhibitors now account for most of them; pregnancy, low food intake and alcohol use are other causes. Treatment for both crises starts the same way: isotonic IV fluids first, a potassium check before insulin (nursing texts and exam items use 3.3 mEq/L as the cutoff; the 2024 ADA-led consensus delays insulin until potassium is above 3.5 mmol/L, the same number in mEq/L), then an IV insulin infusion, with dextrose added as the glucose falls.

How is type 1 diabetes treated?

Insulin is the treatment, because the pancreas no longer makes enough. ADA recommends that most adults with type 1 diabetes use either an insulin pump or multiple daily injections of basal and mealtime insulin, preferably insulin analogs, which carry less hypoglycemia risk than older human insulins. Clients learn to match mealtime doses to the carbohydrate they eat, and continuous glucose monitoring, often paired with an automated insulin delivery (hybrid closed-loop) pump, improves outcomes compared with fingersticks alone.

  • Basal insulin (such as glargine or degludec, or the basal rate on a pump) covers background needs between meals and overnight. It is continued on sick days and on days without food.
  • Mealtime insulin (rapid-acting lispro, aspart or glulisine, or inhaled insulin) covers carbohydrate at meals and corrects high readings. Confirm the meal is available before giving it.
  • Peak times predict lows. Learn onset, peak and duration for each insulin with the insulin types chart.

Two type 1 situations come up often. First, in the months after diagnosis some clients enter a partial remission, or “honeymoon,” phase: the surviving beta cells make some insulin and insulin needs drop for months or even years. It is temporary, so insulin is adjusted, never stopped. Second, SGLT2 inhibitors are not recommended for glucose control in type 1 diabetes because they raise the risk of DKA.

Type 1 develops in stages. Stage 1 is two or more islet autoantibodies with normal glucose, stage 2 adds abnormal glucose without symptoms, and stage 3 is symptomatic diabetes. Teplizumab, an anti-CD3 antibody first approved in 2022, delays the onset of stage 3 disease in people with stage 2; its current label covers people 1 year and older and, under accelerated approval, children 8 to 17 recently diagnosed with stage 3 disease, to slow the loss of their own insulin production. Donislecel, an islet cell therapy approved in 2023, is reserved for adults whose repeated severe hypoglycemia keeps them from reaching their A1C goal.

Studying diabetes?
Put it to the test with NCLEX-style practice questions — free, full rationale on every answer. No credit card.

Start practicing →

How is type 2 diabetes treated?

Treatment starts with nutrition therapy, physical activity and weight management. For adults at high risk, ADA recommends a diabetes prevention program that targets a weight loss of at least 5-7% plus 150 or more minutes a week of moderate activity; in the Diabetes Prevention Program trial, intensive lifestyle change cut new type 2 diabetes cases by 58% over 3 years. Medicines are then chosen around the client’s other conditions, hypoglycemia risk, weight goals, cost and preferences. Under the 2026 Standards:

  • Clients with atherosclerotic cardiovascular disease or high cardiovascular risk, heart failure or chronic kidney disease should take an SGLT2 inhibitor and/or a GLP-1 receptor agonist with proven benefit, regardless of A1C and with or without metformin. Heart failure specifically calls for an SGLT2 inhibitor.
  • When more glucose lowering is needed and there is no severe hyperglycemia or crisis, GLP-1-based therapy is preferred over insulin.
  • Insulin is considered at any stage when there are symptoms of hyperglycemia, an A1C above 10% or a glucose of 300 mg/dL or higher. The plan can often be simplified once the glucose comes down.
  • Metformin is effective, inexpensive and widely used, and it has historically been the first-line drug.

Type 2 diabetes medications: nursing considerations

Class (examples) How it lowers glucose Key adverse effects Nursing considerations
Biguanide (metformin) Reduces glucose production by the liver; improves insulin sensitivity Diarrhea, bloating and abdominal discomfort; vitamin B12 deficiency; rare lactic acidosis (boxed warning) Give with meals and titrate slowly. Does not cause hypoglycemia on its own. Do not use if eGFR is below 30; starting it at an eGFR of 30-45 is not recommended. May need to be held around iodinated contrast, depending on kidney function and the type of study.
GLP-1 receptor agonists (semaglutide weekly injection or daily tablet, dulaglutide, liraglutide) Increase glucose-dependent insulin release, lower glucagon and slow gastric emptying; promote weight loss Nausea, vomiting, diarrhea; acute pancreatitis; gallbladder disease; boxed warning for thyroid C-cell tumors seen in rodents Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Teach the client to report severe abdominal pain that persists or spreads to the back. Tell the surgical team before procedures (aspiration risk from delayed gastric emptying). Never share pens. Oral semaglutide (Rybelsus or Ozempic tablets): take once daily, first thing in the day, on an empty stomach with no more than 4 oz of plain water; swallow the tablet whole, then wait 30 minutes or more before any food, drink or other oral medicine. The two tablet brands are not interchangeable mg for mg.
Dual GIP/GLP-1 receptor agonist (tirzepatide) Activates both GIP and GLP-1 receptors; injected weekly The same GI effects, pancreatitis warning and boxed warning as GLP-1 receptor agonists Can make oral hormonal contraceptives less effective: switch to a nonoral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) Make the kidneys excrete glucose in the urine Genital yeast infections, urinary tract infections, volume depletion, ketoacidosis that can occur with a normal glucose, rare Fournier gangrene Teach genital hygiene and hydration. Hold before scheduled surgery (empagliflozin at least 3 days) and during acute illness with poor intake. Assess for ketoacidosis when nausea, vomiting, abdominal pain or malaise appear, whatever the glucose. Proven heart failure and kidney benefits.
DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin, alogliptin) Slow the breakdown of the body’s own incretin hormones Usually well tolerated; pancreatitis; severe joint pain; bullous pemphigoid; heart failure risk with some agents, notably saxagliptin Low hypoglycemia risk on their own. Not combined with a GLP-1 receptor agonist (no added benefit). Most need dose changes for kidney function (linagliptin does not). Teach the client to report blisters.
Sulfonylureas (glipizide, glimepiride, glyburide) Trigger insulin release from the pancreas whatever the glucose level Hypoglycemia, which can be prolonged in older adults and in kidney or liver impairment; weight gain Give glipizide about half an hour before a meal. Lows are more likely with skipped meals, heavy exercise, alcohol or more than one glucose-lowering drug. ADA advises avoiding glyburide in older adults. Fluoroquinolones and sulfamethoxazole-trimethoprim can increase the hypoglycemia risk.
Thiazolidinedione (pioglitazone) Improves insulin sensitivity Fluid retention, weight gain, heart failure, fractures Do not use in heart failure. Teach the client to report edema, rapid weight gain or shortness of breath.
Insulin Replaces or supplements the body’s insulin Hypoglycemia, weight gain, lipodystrophy at overused sites High-alert medication. Rotate sites within the same region. In type 2 diabetes it is often combined with a GLP-1 receptor agonist.

What are the newest diabetes medications (2025-2026)?

If you searched for a “new diabetes medication,” here is what changed recently in the U.S., based on current FDA labeling. The NCLEX tests drug classes and nursing actions rather than launch dates, so file each one under its class.

  • Once-weekly basal insulin. Insulin icodec (Awiqli) and insulin efsitora alfa (Onswik) were approved in 2026 for adults with type 2 diabetes. Each is injected once a week on the same day from a concentrated pen and must never be drawn into a syringe. The efsitora label says it is not recommended in type 1 diabetes because of the risk of severe hypoglycemia. Both labels allow a missed dose to be given within 4 days and call for more frequent glucose checks afterward.
  • Rapid-acting insulin biosimilars. Insulin aspart-szjj (Merilog) and insulin aspart-xjhz (Kirsty) were approved in 2025. Nursing care matches insulin aspart: inject 5-10 minutes before a meal and rotate sites.
  • Expanded incretin labels. Semaglutide injection (Ozempic) is labeled to reduce the risk of sustained kidney function decline, kidney failure and cardiovascular death in adults who have type 2 diabetes with chronic kidney disease. Oral semaglutide, now sold as Rybelsus and as Ozempic tablets, gained an indication in October 2025 to lower the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in high-risk adults with type 2 diabetes. Tirzepatide (Mounjaro) added children 10 years and older with type 2 diabetes (December 2025) and reduction of major cardiovascular events (August 2026).
  • Oral GLP-1 receptor agonist orforglipron (Foundayo). Approved in 2026 as a once-daily tablet, but its label is for weight management in adults with obesity or overweight, not for glucose control.
  • Teplizumab (Tzield). Its indications were updated in June 2026 (see the type 1 section above).

Hypoglycemia: ADA levels and the rule of 15

ADA calls hypoglycemia often the major limiting factor in glucose management for both types, and the risk is highest with insulin and sulfonylureas. It is classified in three levels:

Level Definition What it means
Level 1 Glucose below 70 mg/dL and 54 mg/dL or higher Clinically important even without symptoms; treat with fast-acting carbohydrate
Level 2 Glucose below 54 mg/dL Threshold where neuroglycopenic symptoms begin; needs immediate action
Level 3 A severe event with altered mental or physical status that needs another person’s help, at any glucose level Glucagon, or IV dextrose in the hospital

Rule of 15 for a client who is awake and can swallow: give fast-acting carbohydrate, preferably glucose: 15 g for most people, while 5-10 g is usually enough for clients using an automated insulin delivery pump (ADA 2026). If a recheck after 15 minutes is still under 70 mg/dL, treat again. When it is back in range, a meal or snack prevents a repeat low. Avoid high-fat or high-protein foods for the first treatment; fat slows the glucose rise, and protein can increase insulin secretion.

If the client cannot swallow safely or is unconscious: give nothing by mouth. Give glucagon (such as 3 mg intranasal, or an injectable form) or, in the hospital, IV dextrose. Turn an unconscious client onto their side, and give oral carbohydrate once they can swallow safely. ADA recommends that glucagon be prescribed for everyone taking insulin or at high risk for hypoglycemia, with ready-to-use forms preferred.

Older adults and clients taking beta-blockers may not recognize hypoglycemia as easily, and clients with long-standing diabetes or repeated lows can lose their warning symptoms (impaired hypoglycemia awareness). The hypoglycemia vs hyperglycemia guide covers recognition and first actions in detail.

What are the sick-day rules for diabetes?

Illness and stress release hormones that raise blood glucose, even in a client who is barely eating. That is why a classic wrong answer on sick-day items is “skip the insulin because you are not eating.”

  • Keep taking basal insulin. ADA states that people on intensive insulin therapy should not stop or hold basal insulin even if they are not eating; the care team gives dose-adjustment instructions.
  • Check glucose more often than usual, as the written sick-day plan directs.
  • Check ketones. ADA suggests testing every 4-6 hours while sick, especially in type 1 diabetes and other ketosis-prone clients. Clients on SGLT2 inhibitors can develop ketoacidosis with a near-normal glucose.
  • Drink fluids. If keeping water down is hard, take small sips about every 15 minutes. If the client cannot eat, simple carbohydrates such as regular soda, gelatin or ice pops help prevent lows.
  • Review other diabetes drugs with the prescriber. ADA advises considering holding metformin and SGLT2 inhibitors when oral intake cannot be maintained or kidney injury is a concern; GLP-1 receptor agonists may need to be held during significant vomiting or diarrhea.
  • Call the provider for vomiting or diarrhea more than three times in 24 hours, a fever over 101°F for 24 hours, high ketones, or DKA warning signs such as fruity breath, abdominal pain, trouble breathing or confusion.

How do you teach diabetic foot care?

Neuropathy removes the warning pain of a blister or a pebble in the shoe, and peripheral artery disease slows healing, so small injuries can become ulcers and amputations. ADA recommends neuropathy screening at the diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1, then at least yearly, plus a comprehensive foot exam with 10-g monofilament testing at least once a year. Clients with lost sensation or a prior ulcer have their feet inspected at every visit. The first dilated eye exam follows a similar logic: at diagnosis for type 2, because years of unrecognized hyperglycemia may already have caused damage, and 5 years after onset for type 1.

Teach the client to:

  • Inspect both feet every day, including between the toes, with a mirror or someone’s help if needed.
  • Wash both feet each day in warm water, never hot; test it with an elbow or a thermometer (90-95°F is safe), and do not soak the feet.
  • Dry carefully between the toes. Moisturize the top and sole of each foot, but keep lotion out from between the toes.
  • Trim toenails straight across. Do not cut corns or calluses or use over-the-counter removers; ask a podiatrist.
  • Wear shoes and socks at all times, never walk barefoot (even indoors), avoid open-toed shoes and feel inside each shoe for objects before wearing it.
  • Keep feet away from heating pads, hot water bottles and heaters.
  • Stop smoking, and report any cut, blister, redness, swelling or sore right away.

What is gestational diabetes?

Gestational diabetes (GDM) is diabetes diagnosed in the second or third trimester that was not clearly present before pregnancy. Clients who have risk factors (for example, prior GDM, or overweight plus a parent or sibling with diabetes) are tested for undiagnosed diabetes at the first prenatal visit, before 15 weeks, and testing all pregnant clients at that visit may be considered. Pregnant clients not already found to have diabetes are then screened for GDM at 24-28 weeks.

  • One-step test: a fasting 75-g OGTT. GDM is diagnosed if any value is met or exceeded: fasting 92 mg/dL, 1 hour 180 mg/dL, 2 hours 153 mg/dL.
  • Two-step test: a nonfasting 50-g glucose load; if the 1-hour value is at or above the cutoff (130, 135 or 140 mg/dL, by protocol), a fasting 100-g OGTT follows.
  • Treatment: lifestyle change is the foundation and is enough for many clients. Insulin is the preferred medication when goals are not met; metformin and glyburide cross the placenta and are not first-line. Glucose goals: under 95 mg/dL fasting, and under 140 mg/dL at 1 hour or under 120 mg/dL at 2 hours after meals.
  • Newborn: diabetes in pregnancy raises the risk of macrosomia and neonatal hypoglycemia, so watch the newborn’s glucose.
  • After delivery: do a 75-g OGTT between 4 and 12 weeks postpartum (preferred over A1C at that point), then screen every 1-3 years for life, because a history of GDM raises the later risk of type 2 diabetes.

Sample NCLEX-style type 1 vs type 2 diabetes questions

These 10 items are written for this page. Choose an answer to check it, then read why each option is right or wrong. For more practice on DKA, the rule of 15 and insulin, work through the diabetes practice questions and the endocrine practice questions, and review the wider system in the NCLEX endocrine review.

Question 1 · Type 1 or type 2?

A routine physical finds an A1C of 8.4% in a 29-year-old client, and diabetes is diagnosed. Which finding in the client’s chart most strongly suggests type 1 rather than type 2 diabetes?

  • A A BMI of 33 kg/m2 with dark, velvety skin at the back of the neck
  • B Both parents and an older sister take metformin for diabetes
  • C A positive glutamic acid decarboxylase (GAD65) autoantibody test
  • D A blood pressure of 142/90 mm Hg and elevated triglycerides
Show answer & rationale
Correct answer: C

GAD65 autoantibodies are a marker of autoimmune beta-cell destruction, the defining feature of type 1 diabetes, including forms that begin slowly in adulthood. ADA recommends islet autoantibody testing for adults whose features overlap with type 1. A positive result changes care: the client will need insulin, often sooner than expected, and is at risk for DKA.

(A) is incorrect because obesity with acanthosis nigricans (dark, velvety skin in body folds) reflects insulin resistance, the hallmark of type 2 diabetes. (B) is incorrect because several relatives taking metformin suggests a family pattern of type 2 diabetes, which raises type 2 risk; it does not point to autoimmunity. (D) is incorrect because hypertension and high triglycerides are features of metabolic syndrome and insulin resistance, which favor type 2.

Question 2 · Diagnostic criteria

The nurse reviews laboratory results for four adults who are not pregnant and have no known diagnosis of diabetes. Which result is enough on its own to diagnose diabetes, without a confirmatory test?

  • A Random plasma glucose of 238 mg/dL with thirst, frequent urination and weight loss
  • B Fasting plasma glucose of 131 mg/dL at a routine checkup, with no symptoms reported
  • C A1C of 6.2% in a client whose mother and older brother both have type 2 diabetes
  • D 2-hour value of 186 mg/dL on a 75-g glucose tolerance test ordered for screening
Show answer & rationale
Correct answer: A

ADA accepts a single random plasma glucose at or above 200 mg/dL as diagnostic when the client has classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or is in a hyperglycemic crisis. In every other situation, two abnormal results are needed.

(B) is incorrect because 131 mg/dL is above the 126 mg/dL fasting cutoff, but a single result without symptoms or a crisis must be confirmed by a second abnormal result, from a different test on the same sample or a test on a second sample, before diabetes is diagnosed. (C) is incorrect because 6.2% is within the prediabetes A1C range of 5.7-6.4%; diabetes requires 6.5% or higher. (D) is incorrect because 186 mg/dL is in the 2-hour OGTT range of 140-199 mg/dL, impaired glucose tolerance (prediabetes); diabetes requires 200 mg/dL or higher. Clients C and D have prediabetes and need teaching and yearly retesting; client B needs a confirmatory test.

Question 3 · Incretin teaching (SATA)

A 34-year-old who uses an oral contraceptive and has type 2 diabetes is starting weekly tirzepatide injections. Which client statements show that the teaching was understood? Select all that apply.

  • A “I’ll call my provider if I get severe stomach pain that goes through to my back.”
  • B “I can take this even though my sister had medullary thyroid cancer, since I never had it.”
  • C “I’ll also use condoms for 4 weeks after starting and after each dose increase.”
  • D “If I remember a missed dose 6 days later, I’ll inject it then and keep my usual day.”
  • E “Since it slows stomach emptying, I’ll tell the surgical team I’m on it before anesthesia.”
  • F “I’ll stop the injections if I feel sick to my stomach during the first few weeks.”
Show answer & rationale
Correct answer: A, C, E

(A) is correct because severe, persistent abdominal pain, sometimes spreading to the back, can signal acute pancreatitis, a labeled warning for this drug class; the drug is stopped if pancreatitis is suspected. (C) is correct because tirzepatide delays gastric emptying and can make oral hormonal contraceptives less effective, so the label advises switching to a nonoral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. (E) is correct because tirzepatide slows gastric emptying, which has been linked to rare pulmonary aspiration during general anesthesia or deep sedation, and the label tells clients to inform providers before any planned surgery or procedure.

(B) is incorrect because medullary thyroid carcinoma in a family member is a contraindication on its own, even if the client never had it; so are a personal history and MEN 2. Tirzepatide carries a boxed warning for thyroid C-cell tumors. (D) is incorrect because the label allows a missed dose only within 4 days (96 hours); after that the dose is skipped and the next one is taken on the usual day. Injecting on day 6 would put two doses 1 day apart, and the label calls for at least 3 days (72 hours) between doses. (F) is incorrect because nausea is among the most frequent adverse reactions, mostly while the dose is being started or increased, and it often eases over time, so quitting without the provider’s input is the wrong response. The client should report nausea, vomiting or diarrhea that is severe or does not go away, because fluid loss can lead to dehydration and acute kidney injury.

Question 4 · SGLT2 inhibitor safety

A 61-year-old who started dapagliflozin for type 2 diabetes 2 months ago calls the clinic. The client reports a temperature of 101.7°F (38.7°C), feeling unwell, and pain, redness and swelling between the genitals and the anus that have worsened since yesterday. How should the nurse respond?

  • A “Yeast infections are common with this medicine. Try an over-the-counter antifungal cream.”
  • B “Drink extra fluids today, and call back if the pain is worse tomorrow.”
  • C “Apply warm compresses, and take your next dose of dapagliflozin as scheduled.”
  • D “You need to be seen right away. Please go to the emergency department now.”
Show answer & rationale
Correct answer: D

Pain, tenderness, redness or swelling in the genital or perineal area together with fever or malaise in a client taking an SGLT2 inhibitor must be evaluated immediately for necrotizing fasciitis of the perineum (Fournier gangrene). It is rare but life-threatening, it needs urgent medical and often surgical treatment, and the drug is stopped if it is suspected.

(A) is incorrect because genital yeast infections are common with SGLT2 inhibitors, but fever, malaise and worsening painful swelling are red flags beyond a simple yeast infection, and self-treatment delays care. (B) is incorrect because waiting a day lets a rapidly spreading infection progress; fluids do not address it. (C) is incorrect because deep soft-tissue infection cannot be managed with warm compresses at home, and the label says to stop the SGLT2 inhibitor when necrotizing fasciitis is suspected.

Question 5 · Hypoglycemia risk by drug class

Four clients with type 2 diabetes each missed lunch because of diagnostic testing. Whose glucose should the nurse check first for hypoglycemia?

  • A A 52-year-old taking metformin 1,000 mg with breakfast and dinner
  • B An 81-year-old taking glyburide, with an eGFR of 38 mL/min/1.73 m2
  • C A 67-year-old taking sitagliptin 100 mg daily along with lisinopril
  • D A 74-year-old with heart failure taking furosemide and dapagliflozin 10 mg daily
Show answer & rationale
Correct answer: B

Sulfonylureas make the pancreas release insulin whatever the glucose level, so missing a meal can drop the glucose too low. Glyburide is long acting with active metabolites, reduced kidney function slows its clearance, and older adults are more vulnerable; ADA advises avoiding glyburide in older adults and generally not using it in chronic kidney disease. Sulfonylurea labels also warn that hypoglycemia can be prolonged and is harder to recognize in older adults. The nurse checks this client’s glucose first and gives food or treatment based on the result.

(A) is incorrect because metformin lowers liver glucose output and does not cause hypoglycemia when used alone. (C) is incorrect because DPP-4 inhibitors raise insulin in a glucose-dependent way, so the hypoglycemia risk is low when used alone. (D) is incorrect because SGLT2 inhibitors work through urinary glucose loss and carry a low hypoglycemia risk on their own; with a loop diuretic, the bigger concern for this client is volume depletion.

Question 6 · Type 1 honeymoon phase

A 16-year-old whose type 1 diabetes was diagnosed 10 weeks ago says, “My readings keep running low and my provider lowered my insulin. I think my diabetes is going away. Can I stop taking insulin?” How should the nurse reply?

  • A “Yes. Once your readings have stayed normal for a full week, you can safely stop your insulin.”
  • B “Your pancreas may be making some insulin again, so ask your provider about switching to a pill.”
  • C “Low readings this early mean you were misdiagnosed and most likely have type 2 diabetes.”
  • D “Your pancreas may still make some insulin, but this phase is temporary. Keep taking insulin.”
Show answer & rationale
Correct answer: D

Soon after a type 1 diagnosis, many people enter a partial remission, or honeymoon, phase in which surviving beta cells make some insulin and insulin needs drop for a time. The autoimmune process continues, so insulin needs rise again, and stopping insulin risks hyperglycemia and DKA. The plan is to keep taking insulin, with dose reductions made by the provider to prevent lows.

(A) is incorrect because without insulin a person with type 1 diabetes can develop DKA, and the normal readings depend partly on the insulin the client is still taking. (B) is incorrect because, although surviving beta cells may make some insulin for a time, beta-cell destruction continues and oral agents do not replace insulin in type 1 diabetes. (C) is incorrect because falling insulin needs early in type 1 diabetes are expected and do not mean the diagnosis was wrong; autoantibody testing, not a remission phase, guides classification.

Question 7 · Gestational diabetes treatment

At 30 weeks’ gestation, a client being treated for gestational diabetes has followed medical nutrition therapy and walked daily for 2 weeks. Her log shows most fasting glucose values at 101-108 mg/dL and most 1-hour post-meal values at 150-165 mg/dL. Which treatment should the nurse anticipate?

  • A Starting insulin, with doses adjusted to the glucose log
  • B Starting glyburide, because it does not cross the placenta
  • C Starting a weekly semaglutide injection to limit weight gain
  • D Continuing nutrition therapy alone and rechecking in 4 weeks
Show answer & rationale
Correct answer: A

In pregnancy, ADA sets glucose goals of under 95 mg/dL fasting and under 140 mg/dL 1 hour (or under 120 mg/dL 2 hours) after meals. This client is above both goals despite lifestyle therapy, so medication is needed, and ADA names insulin as the preferred agent for gestational diabetes. None of the available human insulin preparations have been shown to cross the placenta.

(B) is incorrect because glyburide does cross the placenta (cord levels are about 50-70% of maternal levels) and has been linked to more neonatal hypoglycemia and macrosomia than insulin; ADA says it should not be a first-line agent. (C) is incorrect because GLP-1 receptor agonists lack long-term safety data in pregnancy and are not recommended, whatever the weight goal. (D) is incorrect because 2 weeks of values above goal despite nutrition therapy and activity show that lifestyle change alone is not enough; waiting another 4 weeks prolongs fetal exposure to hyperglycemia, which raises the risk of macrosomia and neonatal hypoglycemia.

Question 8 · Type 2 features (SATA)

A nurse is preparing a teaching session on how type 2 diabetes differs from type 1 diabetes. Which statements belong in the session? Select all that apply.

  • A “Type 2 diabetes does not develop in children, so it can be ruled out in an overweight teen.”
  • B “Most people with type 2 diabetes have insulin resistance and declining insulin secretion.”
  • C “Type 2 diabetes may cause no symptoms for years and is often found through screening.”
  • D “Islet autoantibodies are usually present when type 2 diabetes is first diagnosed.”
  • E “Hyperglycemic hyperosmolar state is more typical of type 2 diabetes than of type 1.”
  • F “Many people with type 2 diabetes eventually need insulin to reach their glucose goals.”
Show answer & rationale
Correct answer: B, C, E, F

(B) is correct because ADA defines type 2 diabetes as a nonautoimmune, progressive loss of insulin secretion, frequently on a background of insulin resistance. (C) is correct because hyperglycemia develops gradually, so type 2 often goes undiagnosed for years; that is why adults are screened starting at age 35. (E) is correct because HHS is more typically associated with type 2 diabetes, especially in older adults, since remaining insulin limits ketone production. (F) is correct because type 2 diabetes is progressive, and many people eventually need insulin; ADA advises considering it when there are symptoms of hyperglycemia, an A1C above 10% or a glucose of 300 mg/dL or higher.

(A) is incorrect because type 2 diabetes occurs at any age, including in children and teens, so age alone cannot rule it out; ADA supports risk-based screening of youth with overweight or obesity after puberty or age 10. (D) is incorrect because islet autoantibodies mark autoimmune (type 1) diabetes; a positive result in an adult points to type 1, including slowly progressive adult-onset forms.

Question 9 · Foot assessment priority

A 70-year-old has type 2 diabetes complicated by peripheral neuropathy. During a foot assessment, the nurse notes these findings. Which one should the nurse follow up on first?

  • A Dry, flaky skin over both heels and the soles of the feet
  • B Thick, yellowed toenails on both great toes that are hard to trim
  • C A painless, draining open area on the ball of the right foot
  • D Reduced vibration sense at both great toes with a 128-Hz tuning fork
Show answer & rationale
Correct answer: C

A draining open area is a foot ulcer with possible infection. Because neuropathy removes protective pain, the client may not have noticed it, and diabetic foot ulcers can progress to deep infection and amputation without prompt treatment. The nurse assesses the wound, the surrounding skin and the pedal pulses, documents the findings and notifies the provider for wound care and possible referral.

(A) is incorrect because dry heels call for teaching (lotion on the top and sole of each foot, not between the toes) but are not urgent. (B) is incorrect because thickened, discolored nails need routine foot or podiatry care, not same-day action. (D) is incorrect because reduced vibration sense confirms the known neuropathy and guides teaching and footwear, but it is a chronic finding rather than an acute problem.

Question 10 · Metformin safety

A 47-year-old started metformin for type 2 diabetes 3 weeks ago. Which report from the client needs the nurse’s follow-up right away?

  • A “I had loose stools and bloating the first week, but it’s better now that I take it with dinner.”
  • B “I’ve had muscle aches, I feel unusually sleepy, and I get short of breath doing very little.”
  • C “My fasting sugar this morning was 138, a bit higher than my goal.”
  • D “I haven’t had a single low blood sugar episode since I started taking it.”
Show answer & rationale
Correct answer: B

Muscle aches (myalgias), unusual sleepiness (somnolence) and respiratory distress are among the subtle, nonspecific early symptoms of metformin-associated lactic acidosis described in the boxed warning. It is rare but can be fatal, so the nurse arranges urgent evaluation and notifies the provider; if lactic acidosis is suspected, metformin is stopped.

(A) is incorrect because GI upset is the principal adverse effect of metformin and often improves with slow titration, extended-release forms and taking it with food. (C) is incorrect because 138 mg/dL, while above the usual premeal goal of 80-130 mg/dL, is not an emergency early in treatment; it calls for ongoing monitoring. (D) is incorrect because metformin alone does not cause hypoglycemia, so the absence of lows is expected.

Frequently Asked Questions

What is the main difference between type 1 and type 2 diabetes?

Type 1 is autoimmune: the beta cells are destroyed, insulin is needed from diagnosis, and DKA is the typical crisis. Type 2 (90-95% of cases) is insulin resistance with a slow decline in insulin secretion; it is often managed first with lifestyle change and non-insulin medicines, and HHS is its more typical crisis.

Can type 2 diabetes turn into type 1 diabetes?

No. Type 2 diabetes can progress until insulin is needed, but it does not become autoimmune type 1 diabetes. Some adults first labeled as having type 2 are later found to have slowly progressive autoimmune diabetes, often called LADA, which ADA classifies as type 1. Islet autoantibody testing identifies them.

Which is worse, type 1 or type 2 diabetes?

Neither is mild. Both cause the same long-term complications when glucose stays high, including eye, nerve, kidney and cardiovascular disease. Type 1 carries a faster risk of DKA if insulin is missed. Type 2 often goes undiagnosed for years, so complications can already be present at diagnosis.

How is diabetes diagnosed?

The ADA 2026 thresholds are an A1C at or above 6.5%, a fasting plasma glucose at or above 126 mg/dL, a 2-hour value at or above 200 mg/dL on a 75-g OGTT, or a random glucose at or above 200 mg/dL with classic symptoms or a hyperglycemic crisis. That last finding is enough on its own; otherwise, two abnormal results are needed, from two tests on the same sample or the same test repeated.

What is the newest medication for diabetes?

Recent U.S. approvals include two once-weekly basal insulins for adults with type 2 diabetes, insulin icodec and insulin efsitora alfa (2026), and two rapid-acting insulin aspart biosimilars (2025). Labels also expanded: oral semaglutide (Rybelsus and Ozempic tablets) gained a cardiovascular risk-reduction indication in October 2025, and tirzepatide added one in August 2026. The oral GLP-1 receptor agonist orforglipron was approved in 2026 for weight management, not glucose control.

Ready to test your diabetes knowledge? Practice free NCLEX-style questions with full rationales for every answer, no credit card required.

Practice questions like these

Put it to the test with NCLEX-style practice questions — free, full rationale on every answer. No credit card.

Start Practicing Free

Sources

Sources checked October 2026.